Wave Life Sciences Ltd. — Director's Dealing 2017

Mar 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2017-03-29

Reporting Person: Tanaka Masaharu (Director, 10% Owner)
Reporting Person: Kagoshima Shinsangyo Sousei Investment Limited Partnership (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-29	Ordinary Shares	S	433825	$24.91	Disposed	2794865	Indirect

Footnotes

F1: The aggregate purchase price for the 433,825 Ordinary Shares was 1,199,998,712 Japanese yen. The purchase price per share in Column 4 of Table I was calculated based on the aggregate purchase price divided by the number of Ordinary Shares sold. The purchase price per share is shown in U.S. dollars and was converted based on the currency exchange rate as of the transaction date, March 29, 2017, rounded to the nearest whole cent.

F2: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka, a director of the Issuer, is the representative director of Kagoshima Development Co., Ltd., the general partner of KSS and may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Tanaka disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.